

- Achkar, J.P., 2010. Inflammatory Bowel Disease.
Available from:
http://www.theportlandclinic.com/wpcontent/uploads/2014/05/tpc_inflammatoryboweldisease-achkar_10572.pdf
- Ahmad, T., Satsangi, J., McGovern, D., Bunce, M., Jewell, D.P., 2001. The genetics of inflammatory bowel disease. *Aliment Pharmacol Ther.* 15: 731-48.
- Allocca, M., Jovani, M., Fiorino, G., Schreiber, S., Danese, S., 2013. Anti-IL-6 Treatment for Inflammatory Bowel Diseases: Next Cytokine, Next Target. *Current Drug Targets* 14: 1508-1521.
- Al-Mofarreh, M. A. and Al-Mofleh, I. A., 2013. Emerging inflammatory bowel disease in Saudi outpatients: a report of 693 cases. *Saudi J. Gastroenterol.* 19: 16–22.
- Archampong, T. N., Nkrumah, K. N., 2013. Inflammatory bowel disease in Accra: what new trends. *West Afr. J. Med.* 32: 40–44.
- Atreya, R., Mudter, J., Finotto, S., Mullberg, J., Jostock, T., Wirtz, S., *et al.*, 2000. Blockade of interleukin-6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn's disease and experimental colitis in vivo. *Nat Med.* 6:583-588.
- Bagaskoro, M.R., Ratnasari, N., Asdie, R.H., 2013. Gambaran Profil Darah Lengkap pada Pasien Diare Kronis karena Inflammatory Bowel Disease di RSUP Dr. Sardjito pada Tahun 2010-2013.
- Balding, J., Livingstone, W.J., Conroy, J., Mynett-Johnson, L., Weir, D.G., Mahmud, N., *et al.*, 2004. Inflammatory bowel disease: the role of inflammatory cytokine gene polymorphisms. *Mediators Inflamm.* 13: 181-7.
- Bamias, G., Nyce, M.R., De La Rue, S.A., Cominelli, F., 2005. New Concepts in the Pathophysiology of Inflammatory Bowel Disease. *Ann Intern Med.* 143:895-904.
- Baumgart, D.C., Metzke, D., Guckelberger, O., Pascher, A., Grotzinger, C., Przesdzing, I., *et al.*, 2011. Aberrant plasmacytoid dendritic cell distribution and function in patients with Crohn's disease and ulcerative colitis. *Clin Exp Immunol.* 166: 46-54.
- Bernardo, D., Vallejo-Diez, S., Mann, E.R., Al Hassi, H.O., Martinez-Abad, B., Montalvillo, E., *et al.*, 2012. IL-6 promotes immune responses in human ulcerative colitis and induces a skinhoming phenotype in the dendritic cells and T cells they stimulate. *Eur J Immunol.* 42: 1337-53.
- Bernstein, C.N., Fried, M., Krabshuis, J.H., Cohen, H., Eliakim, R., Fedail, S., *et al.*, 2009. World Gastroenterology Global Guidelines, Inflammatory bowel disease: a global perspective.
Available from:
http://www.sages.co.za/content/images/inflammatory_bowel_%20disease.pdf
- Bonen, D.K. and Cho, J.H., 2003. The genetics of inflammatory bowel disease. *Gastroenterology* 124:521-36.
- Boulanger, M.J., Chow, D.C., Brevnova, E.E., Garcia, K.C., 2003. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. *Science* 300: 2101-4.



- Bouma, G. and Strober, W., 2003. The immunological and genetic basis of inflammatory bowel disease. *Nat Rev Immunol.* 3:521-33.
- Brand, S., 2009. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17cells in the pathogenesis of Crohn's disease. *Gut*58: 1152-67.
- Cooney, R.M., Warren, B.F., Altman, D.G., Abreu, M.T., Travis, S.P.L., 2007. Outcome measurement in clinical trials for ulcerative colitis:towards standardization. *Trials* 8:17.
- Cosnes, J., Gower-Rousseau, C., Seksik, P., Cortot, A., 2011. Epidemiology and natural history of inflammatory bowel diseases.*Gastroenterology* 140: 1785–1794.
- Crohn's and Colitis Foundation of America, 2014. The Facts about Inflammatory Bowel Disease.
Available from:
<http://www.crohnscolitisfoundation.org/assets/pdfs/updatedibdfactbook.pdf>
- Dahlan, S., 2011. *Statistik untuk Kedokteran dan Kesehatan*. Salemba Medika, Jakarta.
- Danese, S., Sans, M., Fiocchi, C., 2004.Inflammatory bowel disease: the role of environmental factors. *Autoimmun Rev.* 3:394-400.
- Djojoningrat, D., 2014. Inflammatory bowel disease. Dalam: Sudoyo A.W., Setiyohadi, B (Ed.): *Buku ajar ilmu penyakit dalam*. Edisi keenam, hal 1814-1822. Interna Publishing, Jakarta.
- Dong, J., Teng, G., Wei, T., Gao, W., Wang, H., 2016. Methodological Quality Assessment of Meta-Analyses and Systematic Reviews of Probiotics in Inflammatory Bowel Diseases and Pouchitis. *Plos One.*10:744-55.
- Duerr, R.H.,2003. Update on the genetics of inflammatory bowel disease. *J Clin Gastroenterol.* 37:358-67.
- D'Haens, G., Sandborn, W.J., Feagan, B.G., Geboes, K., Hanauer, S.B.,Irvine, E.J., *et al.*, 2007. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults withulcerative colitis. *Gastroenterology* 132:763–86.
- Fiocchi, C., 2002. Inflammatory bowel disease, current concepts of pathogenesis and implications for therapy. *Minerva Gastroenterol Dietol.* 48: 215-26.
- Firmansyah, M.A., 2013. Perkembangan Terkini Diagnosis dan Penatalaksanaan Inflammatory Bowel Disease. *Cermin Dunia Kedokteran* 40 (4): 247-252.
- Ford, A.C., Achkar, J.P., Khan, K.J., Kane, S.V., Talley, N.J., Marshall, J.K., *et al.*, 2011. Efficacy of 5-Aminosalicylates in ulcerative colitis: systematic review and meta-analysis. *Am J Gastroenterol.* 106: 601-16.
- Gabay, C., 2006. Interleukin-6 and chronic inflammation. *Arthritis Research & Therapy* 8(Suppl 2):S3.
- Guerreiro, C.S., Ferreira, P., Tavares, L., Santos, P.M., Neves, M., Brito, M., *et al.*, 2009. Fatty acids, IL6, and TNF alpha polymorphisms: an example of nutrigenetics in Crohn's disease. *Am J Gastroenterol.* 104: 2241-9.
- [Hanauer, S.B.](#), [Sandborn, W.J.](#), [Kornbluth, A.](#), [Katz, S.](#), [Safdi, M.](#), [Woogen, S.](#), *et al.*, 2005. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. [Am J Gastroenterol.](#)100(11):2478-85.
- Hartman, C., Eliakim, R., Shamir, R., 2009. Nutritional status and nutritional therapy in inflammatory bowel diseases. *World J Gastroenterol.* 15 (21): 2570-2578.
- Hebuterne, X., 2009. Nutritional consequences and nutrition therapy in Crohn's disease. *Gastroenterol Clin Biol.* 33 (9): 73159-8.
- Hendy, P. and Hart, A., 2013. Review of Crohn's Disease. *EMJ Gastroenterol.* 1:116-123.



- Holtkamp, W., Stollberg, T., Reis, H.E., 1995. Serum interleukin-6 is related to disease activity but not disease specificity in inflammatory bowel disease. *J Clin Gastroenterol.* 20: 123-6.
- Hosokawa, T., Kusugami, K., Ina, K., 1999. Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease. *J Gastroenterol Hepatol.* 14: 987-96.
- Hyams, J.S., Fitzgerald, J.E., Treem, W.R., Wyzga, N., Kreutzer, D.L., 1993. Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. *Gastroenterology*104: 1285-92.
- Janeway,Jr., C.A. and Medzhitov, R., 2002. Innate immune recognition. *Annu Rev Immunol.* 20: 197-216.
- Jones, S.C., Crabtree, J.E., Rembacken, B.J., 1994. Mucosal interleukin-6 secretion in ulcerative colitis. Effects of anti-inflammatory drugs and T-cell stimulation. *Scand J gastroenterol.* 29 (8): 722-8.
- Jones, S.A., Scheller, J., Rose-John, S., 2011. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. *J Clin Invest.* 121: 3375-83.
- Kaplanski, G., Marin, V., Montero-Julian, F., Mantovani, A., Farnarier, C., 2003. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. *Trends Immunol.*24:25-29.
- Kelompok Studi Inflammatory Bowel Disease Indonesia, 2011. Konsensus Nasional Penatalaksanaan Inflammatory Bowel Disease (IBD) di Indonesia.
- Kimura, A. and Kishimoto, T., 2010. IL-6: regulator of Treg/Th17 balance. *Eur J Immunol.* 40: 1830-35.
- Kishimoto, T., 2005. Interleukin-6: from basic science to medicine- 40 years in immunology. *Annu. Rev. Immunol.* 23:1.
- Kishimoto, T., 2010. IL-6: from its discovery to clinical applications. *International Immunology* 22 (5): 347-352.
- Korn, T., Bettelli, E., Oukka, M., 2009. IL-17 and Th17 cells. *Annu Rev Immunol.* 27: 485-517.
- Kusugami, K., Fukatsu, A., Tanimoto, M.,1995. Elevation of interleukin-6 in inflammatory bowel disease is macrophage and epithelial cell-dependent. *Dig Dis Sci.* 40: 949-59.
- Kwon, J.H., Keates, S., Bassani, L., Mayer, L.F., Keates, A.C., 2002. Colonic epithelial cells are a major site of macrophage inflammatory protein 3alpha (MIP-3alpha) production in normal colon and inflammatory bowel disease. *Gut*51:818-26.
- Lewis, J.D., Chuai, S., Nessel, L., 2008. Use of the Non-invasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis. *Inflamm Bowel Dis.*14(12): 1660–1666.
- Lodes, M.J., Cong, Y., Elson, C.O., Mohamath, R., Landers, C.J., Targan, S.R., *et al.*, 2004. Bacterial flagellin is a dominant antigen in Crohn disease. *J Clin Invest.* 113 (9):1296-306.
- Loftus, E.V., Silverstein, M., Sandborn, W., Tremaine, W., Harmsen, W., Zinsmeister, A., 2000. Ulcerative colitis in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. *Gut* 46, 336–343.
- Loftus, E.V.,2004. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences.*Gastroenterology* 126: 1504–1517.
- Loftus, E.V. and Bernstein, C.N., 2006. A population-based case control study of potential risk factors for IBD. *Am. J. Gastroenterol.* 101: 993–1002.
- Magro, F., Gionchetti, P., Eliakim, R., 2017. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. *J Crohns Colitis.* 11 (6):649-670.



- Mahid, S., Minor, K.S., Soto, R.E., Hornung, C.A., Galandiuk, S., 2006. Smoking and Inflammatory Bowel Disease: A Meta Analysis. *Mayo Clin Proc.* 81 (11): 1462-1471.
- Mahid, S., 2008. Inflammatory bowel disease and African Americans: a systematic review. *Inflamm. Bowel Dis.* 14: 960–967.
- Matzinger, P., 2002. The danger model: a renewed sense of self. *Science* 296: 301-5.
- McNally, P.R., 2013. Use of Anti-TNF α Agents in the Treatment of Moderate to Severe Ulcerative Colitis. *Visible Human Journal of Endoscopy.* 12: 25-29.
- Mitsuyama, K., Sata, M., Tanikawa, K., 1991. Significance of interleukin-6 in patients with inflammatory bowel disease. *Gastroenterol Jpn.* 26 (1): 20-8.
- Mitsuyama, K., Toyonaga, A., Sasaki, E., 1995. Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. *Gut.* 36: 45-9.
- Miyara, M., Gorochov, G., Ehrenstein, M., 2011. Human FoxP3+ regulatory Tcells in systemic autoimmune diseases. *Autoimmun Rev.* 10:744-55.
- Molodecky, N. A., 2012. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology* 142, 46–54.
- Mudter, J. and Neurath, M.F., 2007. IL-6 signaling in inflammatory boweldisease: pathophysiological role and clinical relevance. *Inflamm Bowel Dis.* 13: 1016-23.
- Nakahara, H., Song, J., Sugimoto, M., 2003. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. *Arthritis Rheum.* 48: 1521-9.
- Ng, S.C., Tang, W., Ching, J.Y., Wong, M., Chow, C.M., Hui, A.J., *et al.*, 2013. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn's and colitis epidemiology study. *Gastroenterology* 145: 158–165.
- Nikolaus, S., Bauditz, J., Gionchetti, P., Witt, C., Lochs, H., Schreiber, S., 1998. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin-10 during intestinal inflammation. *Gut*42: 470-6.
- Ordas, I., Eckmann, L., Talamini, M., Baumgart, D.C., Sandborn, W.J., 2012. Ulcerative colitis. *Lancet* 380: 1606-19.
- Papadakis, M.A. and McPhee, S.J., 2015. Current Medical Diagnosis and Treatment. 54th ed. McGraw Hill, New York.
- Parenteau, N.L. and Hardin-Young, J., 2007. The Biological Mechanism Behind Injury and Inflammation: How They Can Affect Treatment Strategy, Product Performance, and Healling. *Wounds* 19 (4): 87-96.
- Reddy, S. I. And Burakoff, R., 2003. Inflammatory bowel disease in African Americans. *Inflamm. Bowel Dis.* 9: 380–385.
- Reimund, J.M., Wittersheim, C., Dumont, S., 1996. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. *J Clin Immunol.* 16: 144-50.
- Reinisch, W., Gasche, C., Tillinger, W., 1999. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse. *Am J Gastroenterol.* 94: 2156-64.
- Rincon, M., 2012. Special issue on Interleukin-6 (IL-6). *International Journal of Biological Sciences.* 8(9):1225-1226.
- Roda, G., Marocchi, M., Sartini, A., Roda, E., 2011. Cytokine Networks in Ulcerative Colitis. *Ulcers.* 9: 380–385.
- Rutgeerts, P., Sandborn, W.J., Feagan, B.G., Reinisch, W., Olson, A., Johanns, J., 2005. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis. *N Engl J Med.* 353: 2462-76.



- Sands, B.E., 2004. From symptoms to diagnosis: Clinical distinction among various forms of intestinal inflammation. *Gastroenterology* 126: 1518-32.
- Satsangi, J., Ho, G.T., Boyapati, R., 2015. Ulcerative Colitis. *Medicine*. 43: 276-281.
- Scheller, J., Chalaris, A., Schmidt-Arras, D., Rose-John, S., 2011. The pro- and anti-inflammatory properties of the cytokine interleukin-6. *Biochimica et Biophysica Acta*. 1813:878–888.
- Schroeder, K.W., Tremaine, W.J., Ilstrup, D.M., 1987. Coated Oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. *N Engl J Med*. 317: 1625-9.
- Siewert, E., Bort, R., Kluge, R., 2000. Hepatic cytochrome p450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent. *Hepatology* 32: 49-55.
- Sokol, H. and Seksik, P., 2010. The intestinal microbiota in inflammatory bowel diseases: time to connect with the host. *Curr Opin Gastroenterol*. 26: 327-31.
- Strober, W., Fuss, I. J., Blumberg, R. S., 2002. The immunology of mucosal models of inflammation. *Annu. Rev. Immunol*. 20: 495–549.
- Strober, W. and Fuss, I.J., 2011. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. *Gastroenterology* 140: 1756-67.
- Su, C., Lewis, J.D., Goldberg, B., 2007. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. *Gastroenterology*. 132:516–26.
- Tanaka, T. and Kishimoto, T., 2012. Targeting Interleukin-6: All the Way to Treat Autoimmune and Inflammatory Diseases. *International Journal of Biological Sciences*. 8(9):1227-1236.
- Teixeira, F.V., Hosne, R.S., Sobrado, C.W., 2015. Management of ulcerative colitis: a clinical update. *J. Coloproctol*. 35 (4): 230-7.
- Thia, K. T., 2008. An update on the epidemiology of inflammatory bowel disease in Asia. *Am. J. Gastroenterol*. 103: 3167–3182.
- Travis, S.P.L., Higgins, P.D.R., Orchard, T., Van Der Woudes, C.J., Panaccione, R., Bitton, A., et al., 2011. Defining remission in ulcerative colitis. *Aliment Pharmacol Ther*. 34: 113–124.
- Ukwenya, A. Y., Inflammatory bowel disease in Nigerians: still a rare diagnosis? *Ann. Afr. Med*. 10: 175–179.
- Umehara, Y., Kudo, M., Nakaoka, R., Kawasaki, T., Shiomi, M., 2006. Serum proinflammatory cytokines and adhesion molecules in ulcerative colitis. *Hepatogastroenterology*. 53: 879-82.
- Vavricka, S.R., Schoepfer, A., Scharl, M., 2015. Extraintestinal Manifestations of Inflammatory Bowel Disease. *Inflamm Bowel Dis*. 21 (8): 1982-1992.
- Walsh, A.J., Ghosh, A., Brain, A.O., Buchel, O., Burger, D., Thomas, S., et al., 2014. Comparing disease activity indices in ulcerative colitis. *Journal of Crohn's and Colitis* 8: 318–325.
- Wine, E., Mack, D.R., Hyams, J., 2013. Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis. *J Crohns Colitis*. 12: 508-9.
- Yamamoto, M., Yoshizaki, K., Kishimoto, T., Ito, H., 2000. IL-6 is required for the development of Th-1 cell-mediated murine colitis. *J Immunol*. 164:4878-4882.
- Yu, Y., Sitaraman, S., Gewirtz, A.T., 2004. Intestinal epithelial cell regulation of mucosal inflammation. *Immunol Res*. 29:55-68.